Romvimza vs Tryvio
A plain-English comparison of two other specialty drugs that may be accessible via NPP.
Side-by-side
| Romvimza | Tryvio | |
|---|---|---|
| Generic name | vimseltinib | aprocitentan |
| Manufacturer | Deciphera Pharmaceuticals (an Ono Pharmaceutical company) | Idorsia Pharmaceuticals |
| Modality | Oral CSF1R tyrosine kinase inhibitor (30 mg twice weekly) | Oral dual endothelin receptor antagonist (once-daily 12.5 mg tablet) |
| Indication | Oncology (tenosynovial giant cell tumor) | Cardiology (resistant hypertension) |
| FDA approval | February 14, 2025 | March 2024 |
When physicians choose Romvimza
Romvimza is typically selected when its mechanism and labeled indication fit the disease subtype. It is manufactured by Deciphera Pharmaceuticals (an Ono Pharmaceutical company) and represents an Oral CSF1R tyrosine kinase inhibitor (30 mg twice weekly) option in Oncology (tenosynovial giant cell tumor).
When physicians choose Tryvio
Tryvio is typically selected when its mechanism aligns better with disease sub-type, prior therapy failure, or safety profile. It is manufactured by Idorsia Pharmaceuticals and represents an Oral dual endothelin receptor antagonist (once-daily 12.5 mg tablet) option in Cardiology (resistant hypertension).
Both drugs - access via NPP
Both Romvimza and Tryvio can be accessed via NPP in most of our covered markets. Choice between them is a clinical decision for the treating physician.
Not medical advice
This comparison is information, not clinical guidance.
Request either drug
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at [email protected]. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 by AI Clinical Review Agent (see Trust & Compliance).